You just read:

Pulmatrix and Mylan Report Positive Pharmacokinetic Bioavailability Data in Pilot Study of PUR0200 in Patients with Chronic Obstructive Pulmonary Disease (COPD)

News provided by

Pulmatrix, Inc.

19 Jul, 2016, 08:30 ET